ArticleBJUI compass2025

PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

Michela Roberto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.